On April 24, 2024, Charles River Laboratories International Inc announced that it has filed a supplement to definitive proxy statement with Securities and Exchange Commission, stating that it committed to the responsible use of animals in every aspect of our business, animals are required by government regulators globally for the development and testing of new medicines and treatments, including complex, cutting-edge biologics, and its extensive and historical commitment to the 4Rs: Refinement, Reduction, Replacement and Responsibility ? underscores Company?s ethical framework to animal research. In addition, the Company recommended the shareholders to vote against the shareholder proposal regarding publish a report on non-human primates imported by the Company, at the annual meeting of shareholders scheduled to be held on May 8, 2024.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
236.3 USD | +0.44% | +3.19% | -0.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.04% | 12.08B | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
+0.39% | 11.96B | |
+21.07% | 11.56B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission